MDR1 gene therapy - Crucell

Drug Profile

MDR1 gene therapy - Crucell

Latest Information Update: 24 Jun 1998

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Crucell
  • Class Chemoprotectants; Gene therapies
  • Mechanism of Action P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bladder cancer; Breast cancer; Non-Hodgkin's lymphoma

Most Recent Events

  • 24 Jun 1998 Discontinued-I for Bladder cancer in Netherlands (Unknown route)
  • 24 Jun 1998 Discontinued-I for Breast cancer in Netherlands (Unknown route)
  • 24 Jun 1998 Discontinued-I for Non-Hodgkin's lymphoma in Netherlands (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top